Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Switching From Efavirenz/Atripla to Rilpivirine Among Patients With Neurocognitive or Neuropsychological Side Effects (SWEAR)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2014 by Azienda Ospedaliera San Gerardo di Monza.
Recruitment status was  Not yet recruiting
Sponsor:
Collaborator:
Gilead Sciences
Information provided by (Responsible Party):
Giuseppe Lapadula, Azienda Ospedaliera San Gerardo di Monza
ClinicalTrials.gov Identifier:
NCT02042001
First received: January 20, 2014
Last updated: NA
Last verified: January 2014
History: No changes posted
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is not yet open for participant recruitment.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: September 2015 (Final data collection date for primary outcome measure)